MetaCap

Cue Biopharma (CUE) vs GridAI Technologies (GRDX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GridAI Technologies (GRDX) has outperformed Cue Biopharma (CUE) over the past year, gaining 20.6% versus a loss of 76.8%. Over five years, CUE leads with a -98.9% price change compared with -100.0% for GRDX. Cue Biopharma is the larger company by market cap ($34.7 million vs $32.4 million), about 1.1 times the size.

Cue Biopharma converts more of its revenue into profit, with a net margin of -96.9% versus -17634.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CUE-76.75%GRDX+20.61%
+172%+38%-96%
Nov 21, 20251 yearNov 20, 2026
CUE-99.07%GRDX-99.99%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CUE versus GRDX key metrics
MetricCUEGRDX
Share price$4.15$3.16
Market cap$34.69M$32.44M
1-day change-7.78%-8.41%
YTD return-54.64%-32.19%
1-year return-76.75%+20.61%
5-year return-98.92%-99.99%
EPS (TTM)$-27.80$-5.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$27.47M$36.25K
Revenue growth (YoY)+195.75%—
Net income (latest FY)$-26.60M$-6.39M
Gross margin—-1813.56%
Operating margin-96.67%-19539.98%
Net margin-96.85%-17634.42%
52-week high$45.50$6.93
52-week low$2.83$1.87
Distance from 52-week high-90.88%-54.39%
Analyst consensusnone—
Avg. price target upside+2020.48%—
Average volume567.02K120.78K
Shares outstanding8.36M10.27M
Employees29—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRDX has outperformed CUE by 97.4 percentage points over the past year.
  • Cue Biopharma is more profitable, keeping -96.9 cents of every revenue dollar as net income versus -17634.4 cents for GridAI Technologies.

About Cue Biopharma

CUE stock →

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About GridAI Technologies

GRDX stock →

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.

Health Care · Biotechnology: Pharmaceutical Preparations

CUE vs GRDX FAQ

Which is bigger, Cue Biopharma or GridAI Technologies?

Cue Biopharma (CUE) is larger, with a market capitalization of $34.69M compared with $32.44M for GridAI Technologies (GRDX).

Which stock has performed better over the past year, CUE or GRDX?

GRDX returned +20.61% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.

Are Cue Biopharma and GridAI Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons